1. Home
  2. AMTB vs AVLN Comparison

AMTB vs AVLN Comparison

Compare AMTB & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$28.69

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$38.37

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMTB
AVLN
Founded
1979
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
AMTB
AVLN
Price
$28.69
$38.37
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$23.67
N/A
AVG Volume (30 Days)
436.0K
163.8K
Earning Date
04-23-2026
N/A
Dividend Yield
1.57%
N/A
EPS Growth
386.36
N/A
EPS
0.97
N/A
Revenue
N/A
N/A
Revenue This Year
$8.29
N/A
Revenue Next Year
$7.67
N/A
P/E Ratio
$29.32
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$24.90
52 Week High
$30.60
$40.17

Technical Indicators

Market Signals
Indicator
AMTB
AVLN
Relative Strength Index (RSI) 54.56 67.65
Support Level $21.68 $26.38
Resistance Level $30.60 $40.08
Average True Range (ATR) 0.63 2.60
MACD -0.25 0.54
Stochastic Oscillator 21.47 94.55

Price Performance

Historical Comparison
AMTB
AVLN

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: